Highlights: Last Open-Label Extension (OLE) study patient successfully completes 12-month treatment period Treatment with NUZ-001 continues to be well-tolerated and shows promising results in extending the life expectancy of patients with MND/ALS Key findings compared to untreated matched controls from the PRO-ACT Historical Database were: NUZ-001 significantly increased survival (χ2=14.1, p=0.00017)...
Latest News
MELBOURNE, Australia — Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, is pleased to provide the following update on preparations for entry into the HEALEY ALS Platform Trial, along with encouraging new data showing that NUZ-001 slows the...
NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington’s disease Treatment prevented hallmark developmental and morphological abnormalities, protected against neuronal cell death, restored delayed haemoglobin production, and rescued BDNF expression following Htt protein knockdown Neurizon plans to initiate additional validation studies in mammalian...
Neurizon has successfully developed a new oral liquid formulation of NUZ-001 for the treatment of ALS The liquid formulation is designed to support patients with all stages of ALS, particularly those with swallowing difficulties such as bulbar onset, ensuring broader access to therapy Developed as part of Neurizon’s patient-centric innovation strategy,...
High levels of NUZ-001 and its major active metabolite NUZ-001 Sulfone cross the blood-brain barrier in a rodent PK study In a repeat of the TDP-43 aggregation assay designed to extend the dose-response curve, both compounds significantly prevented the aggregation of TDP-43 in a patient-derived iPSC neuronal model of ALS...
MELBOURNE, Australia — Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to report positive topline results from the Open-Label Extension (OLE) study of its lead candidate NUZ-001, for the treatment of amyotrophic lateral sclerosis (ALS), the...
MELBOURNE, Australia — Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the Sean M. Healey & AMG Center for ALS at Mass General Brigham has received clearance from the...
Utrecht, Netherlands and Vienna, Austria – Neuroblastoma mainly affects toddlers and young children – in the EU region there are 1500 new cases per year. Neuroblastoma is a malignant tumor of the peripheral nervous system and around 50% of patients are high-risk cases. Recurrences occur frequently, and conventional therapies are...
CAMBRIDGE, Mass. — NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of enrollment of Part 1 of its two-part, Phase 2a clinical trial evaluating the efficacy and safety, of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment...
New multimedia awareness campaign empowers people living with tardive dyskinesia to stand up to stigma and speak openly with their healthcare provider about symptoms and treatment SAN DIEGO, Calif. — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of ConnectING with Carnie™, a multimedia awareness campaign in partnership with Grammy-nominated singer-songwriter and...